OKYO Pharma’s (OKYO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $7.00 price objective on the stock.

OKYO Pharma Stock Performance

NASDAQ:OKYO opened at $1.05 on Wednesday. The stock’s fifty day moving average is $1.04 and its 200 day moving average is $1.25. OKYO Pharma has a fifty-two week low of $0.81 and a fifty-two week high of $2.12.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.